Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-18 Earnings release - Q2 2026

More about the company

Market Cap	5.28M 1.61B 4.58M 4.26M 3.92M 7.4M 504M 7.52M 50.22M 19.72M 251M 19.83M 19.4M 831M	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	5.28M 1.61B 4.58M 4.26M 3.92M 7.4M 504M 7.52M 50.22M 19.72M 251M 19.83M 19.4M 831M	EV / Sales 2026 *	3.56x	EV / Sales 2027 *	2.03x
Free-Float	82.39%	Yield 2026 *	-	Yield 2027 *	-

07-27	L.I.A. Pure Capital Ltd Delivers an Email to Evogene Ltd	CI
07-22	Evogene Ltd. and Eleo Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule Pcsk9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases	CI
07-22	Evogene, ELEO Collaborating to Develop Oral PCSK9 Inhibitors	MT
07-10	L.I.A. Pure Capital Sends Letter to Evogene	CI
07-08	Evogene Ltd. and Blavatnik Center For Drug Discovery at Tel Aviv University Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery	CI
06-24	Evogene Ltd. And Google Cloud Announces Major Milestone In Collaboration Advancing ChemPass AI Toward Autonomous Small Molecule Discovery And Optimization	CI
06-02	Biomica Completes Phase 1 Clinical Study of Bmc128 in Combination with Nivolumab	CI
05-20	Evogene Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-20	Evogene Ltd., Q1 2026 Earnings Call, May 20, 2026
05-20	Evogene Ltd files for offering of 2.45 million ordinary shares by selling shareholder SEC filing	RE
05-18	Evogene Ltd.'S Subsidiary Ag Plenus Ltd. and Bayer Ag to Discontinue Their Herbicide Development Project	CI
04-24	Evogene's Casterra unit eyes castor crop growth in Brazil	RE
04-02	Evogene reports receipt of Nasdaq minimum bid price notification	RE

23-10-02	Alliance Global Starts Evogene at Buy With $1.85 Price Target	MT
23-08-18	Lake Street Adjusts Evogene's Price Target to $3 From $2, Keeps Buy Rating	MT
21-07-29	EVOGENE : Aegis Capital Starts Evogene at Buy	MT
20-12-01	EVOGENE : Cantor Fitzgerald Starts Evogene at Overweight With $9 Price Target	MT

07-30	Evogene Schedules Second Quarter 2026 Financial Results Release	PR
07-22	Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases	PR
07-08	Evogene : and Tel Aviv University’s Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery	PU
06-02	Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica	PR
05-20	Evogene : Q1 2026 Consolidated Financial Statements	PU

Manager	Title	Age	Since
Ofer Haviv CEO	Chief Executive Officer	60	2004-11-30
Gabi Tarcic PRN	Corporate Officer/Principal	-	-
Polina Ravzin PRN	Corporate Officer/Principal	-	2021-12-31

Evogene Ltd Stock TEL AVIV STOCK EXCHANGE

Stocks

IL0011050551

Biotechnology & Medical Research

Valuation: Evogene Ltd

Latest news : Evogene Ltd

Last Transcript: Evogene Ltd

Analysts' recommendations: Evogene Ltd

Press Releases: Evogene Ltd

News in other languages: Evogene Ltd

Quotes and Performance

Managers and Directors: Evogene Ltd

Other Biotechnology & Medical Research

Financials

Company Profile

Director	Title	Age	Since
Ofer Haviv BRD	Director/Board Member	60	-
Leon Recanati BRD	Director/Board Member	77	2010-06-02
Sarit Firon CHM	Chairman	60	2021-05-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EVOGENE LTD	-0.43%	-5.52%	-	-	5.28M
LONZA GROUP AG	-1.40%	+2.59%	-1.71%	+11.28%	48.53B
REVOLUTION MEDICINES, INC.	-2.41%	-0.90%	+411.96%	+495.33%	39.87B
IQVIA HOLDINGS INC.	-1.16%	+12.96%	+28.81%	+7.25%	38.68B
BEONE MEDICINES AG	-1.88%	-3.03%	+5.69%	+53.00%	35.13B
CELLTRION, INC.	-1.74%	+5.12%	+9.58%	+46.02%	29.79B
ASCENDIS PHARMA A/S	-2.85%	-3.92%	-	-	16.08B
MEDPACE HOLDINGS, INC.	-0.21%	-4.04%	+36.40%	+125.75%	16.11B
EUROFINS SCIENTIFIC SE	-0.64%	+2.65%	+3.40%	+13.11%	13.61B
ICON PUBLIC LIMITED COMPANY	-1.19%	-1.32%	-1.73%	-34.37%	12.62B
Average	-1.39%	+1.05%	+61.55%	+89.67%	27.82B
Weighted average by Cap.	-1.60%	+2.03%	+79.16%	+109.15%

	2026 *	2027 *
Net sales	1.48M 453M 1.29M 1.2M 1.1M 2.08M 142M 2.11M 14.11M 5.54M 70.5M 5.57M 5.45M 234M	2.6M 794M 2.26M 2.1M 1.93M 3.64M 248M 3.7M 24.72M 9.71M 124M 9.76M 9.55M 409M
Net income	-16.69M -5.09B -14.48M -13.47M -12.38M -23.39M -1.59B -23.77M -159M -62.31M -793M -62.66M -61.29M -2.63B	-13.92M -4.25B -12.07M -11.23M -10.32M -19.5M -1.33B -19.82M -132M -51.96M -661M -52.25M -51.11M -2.19B
Net Debt	-	-